INCOG, which now employs just more than 400 people in Fishers, plans to have nearly 1,000 people working at its 21-acre campus by 2030.
Read More
Lewis sat down with IBJ to talk about his leadership style and the role of cycling in his life.
Read More
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
The case against Lilly centered on the rebates that drug companies must pay to state Medicaid programs to subsidize some of the cost.
The Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded his company on May 10, 1876.
The move comes as Lilly has embarked on a spree of large acquisitions, including two of its most-expensive transactions ever.
Demand for drugs to combat ticks and other pests was a major factor boosting Elanco Animal Health Inc.’s first quarter results, company executives said Wednesday.
Lilly’s latest commitment at the LEAP District brings the company’s total investment there since 2022 to $18 billion.
The potential savings estimated would be substantial as Americans spent $467 billion on prescription drugs in 2024, according to the most recent government data available.
The settlement is among the largest in a series of settlements by drugmakers, wholesalers and pharmacies in recent years.
The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs that remain illegal under federal law.
Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year.
The judge had been expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the U.S. government.
The criminal sentence Tuesday will mark a major step toward the company finalizing a settlement of thousands of lawsuits it faces over the toll of opioids.
Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
Through the collaboration, Telix and Regeneron expect to develop and commercialize next-generation radiopharmaceutical therapies targeting cancer.
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
The daily oral medication, which will be branded as Foundayo, is expected to begin shipping Monday.
